MedPath

Mobile-based Lifestyle Intervention in Women With Glucose Intolerance After Gestational Diabetes

Not Applicable
Completed
Conditions
Glucose Intolerance
Healthy Lifestyle
Gestational Diabetes
Type 2 Diabetes Mellitus
Interventions
Behavioral: mobile-based lifestyle intervention
Registration Number
NCT03559621
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Brief Summary

Although lifestyle modification programs have been shown to be effective in preventing diabetes in older populations, interventions in women with recent gestational diabetes (GDM) clearly need to be adapted to address their unique barriers to behavior change in order to optimize adherence. The low participating rates in many studies using individual or group sessions, reflect how difficult it is to engage women in the first years postpartum. Since women with glucose intolerance (prediabetes) have the highest risk to develop type 2 diabetes (T2DM), we designed the MELINDA pilot study, a randomized controlled trial with 1 year of follow-up to evaluate the efficacy and feasibility of a telephone -and mobile (app) based lifestyle coaching intervention in women with glucose intolerance after a recent history of GDM to promote a healthy lifestyle.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
240
Inclusion Criteria
  • aged 18 or older
  • GDM based on the 2013 WHO criteria
  • glucose intolerance (prediabetes based on the ADA criteria) based on the 75g OGTT 6-16 weeks after delivery
Exclusion Criteria
  • diabetes;
  • current use of metformin;
  • normal glucose tolerance (ADA criteria);
  • health limitations or treatments which would restrict the participation in the intervention trial.
  • Has no smartphone

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
intervention groupmobile-based lifestyle interventionA mobile-based lifestyle intervention
Primary Outcome Measures
NameTimeMethod
weight-loss goal1 year

reaching the weight-loss goal ≥5% of body weight when overweight or obese or returning to pre-gravid weight if normal BMI

Secondary Outcome Measures
NameTimeMethod
beta-cell function HOMA-B1 year

beta-cell function measured by HOMA-B

physical activity IPAQ1 year

IPAQ questionnaire

Sence of Coherence1 year

Sence of Coherence (SOC) questionnaire

dietary quality1 year

Flemish FFQ

diabetes1 year

development of type 2 diabetes based on the ADA criteria

metabolic syndrome6-16 weeks postpartum

development of a metabolic syndrome based on the WHO criteria

duration breastfeeding1 year

self-designed questionnaire to evaluate duration of breastfeeding

rate exclusive breastfeeding1 year

self-designed questionnaire to evaluate rate of exclusive breastfeeding

depression1 year

CES-D questionnaire

beta-cell function insulinogenic index1 year

beta-cell function measured by insulinogenic index

prediabetes1 year postpartum

prevalence of prediabetes based on the ADA criteria

insulin resistance HOMA-IR1 year

insulin resistance measured by HOMA-IR

beta-cell function ISSI-2 index1 year

beta-cell function measured by ISSI-2 index

insulin resistance Matsuda1 year

insulin resistance measured by Matsuda index

weight loss1 year

mean weight loss

quality of life1 year

SF-36 questionnaire

anxiety1 year

STAI-6 questionnaire

motivation for behavior change1 year

the TSRQ

diabetes risk perception1 year

diabetes risk perception questionnaire

physical activity pedometer1 year

pedometer

Trial Locations

Locations (7)

GZA

🇧🇪

Antwerpen, Belgium

UZA

🇧🇪

Antwerpen, Belgium

AZ Groeninge Kortrijk

🇧🇪

Kortrijk, Belgium

UZ Leuven

🇧🇪

Leuven, Belgium

Imelda Bonheiden

🇧🇪

Bonheiden, Belgium

AZ Klina

🇧🇪

Brasschaat, Belgium

OLV Aalst-Asse

🇧🇪

Aalst, Oost-Vlaanderen, Belgium

© Copyright 2025. All Rights Reserved by MedPath